Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
94717 trials found · Page 139 of 4736
-
New hope for rare cancer: targeted drug trial opens for aggressive salivary gland tumors
Disease control Recruiting nowPhase II open label study designed to evaluate the efficacy and safety of P-Sam in patients with aggressive, solid, NOTCH mutant or p63 low (B7-H4 high) R/M ACC-I patients.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug could delay breast cancer return in High-Risk patients
Disease control Recruiting nowIn this clinical trial, the Sponsor plans to investigate whether patients with HR+/HER2- eBC identified during routine clinical assessments and treatments as having intermediate to high-risk (based on Oncotype DX® or similar tests and on response assessment to 2-6 weeks of preope…
Phase: PHASE3 • Sponsor: West German Study Group • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for kidney cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respective…
Phase: PHASE2 • Sponsor: Brian Rini • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New vaccine-immunotherapy combo aims to shrink head and neck tumors before surgery
Disease control Not yet recruitingHead and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, as over 60% of patients are diagnosed at a locally advanced stage with a high risk of recurrence. Although the landmark KEYNOTE-689 trial established neoadjuvant immune checkpoint inhibitor (…
Phase: PHASE2 • Sponsor: West China Hospital • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
New drug combo aims to halt rare childhood cancers
Disease control Recruiting nowThe purpose of this study is to evaluate the investigational oral drug AMXT 1501 in combination with oral eflornithine (DFMO). An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the w…
Phase: PHASE1, PHASE2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to fight Hard-to-Treat stomach cancers
Disease control Recruiting nowThis study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the stud…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Could a diabetes drug slow MS brain damage? new trial aims to find out.
Disease control Recruiting nowThe goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal v…
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
AI reads heart tests to catch hidden valve disease
Diagnosis Recruiting nowAoS-SEDAI study is an observational, multicenter, retrospective and prospective clinical study. This study aims to assess Willem Artificial Intelligence (AI) ability to distinguish between aortic stenosis (AS) and non-AS patients from 12-lead electrocardiogram (ECG) data.
Sponsor: Idoven 1903 S.L. • Aim: Diagnosis
Last updated May 15, 2026 17:38 UTC
-
New cell therapy aims to tame lupus and scleroderma
Disease control Not yet recruitingThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
AI-Crafted mRNA vaccine takes on advanced cancers in first human test
⭐️ VACCINE ⭐️ Recruiting nowThis is a phase I, open-label, single-arm, single-center, dose-escalation study to evaluate the safety, tolerability, and preliminary anti-tumor efficacy of PAN-NeoVax, an artificial intelligence (AI)-designed pan-cancer neoantigen mRNA vaccine delivered via lipid nanoparticles (…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:06 UTC
-
New hope for advanced head and neck cancer: drug combo plus radiation shows promise
Disease control Not yet recruitingStudy Objectives 1. Primary Objective: The core aim of this study is to investigate whether the sequential approach of Spatially Fractionated Radiotherapy followed by 3 cycles of induction chemotherapy combined with Iparomlimab and Tuvonralimab, definitive chemoradiotherapy,…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Nanchang University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Cord blood transplants offer new hope for young blood cancer patients
Disease control Recruiting nowThe purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Could a Two-Drug start be better for High-Risk PAH patients?
Disease control Recruiting nowPulmonary arterial hypertension (PAH) is a rare, progressive disease associated with poor prognosis, especially in patients with cardiovascular comorbidities. Current guidelines recommend initial combination therapy, but evidence is lacking for patients with significant comorbidi…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 14, 2026 12:01 UTC
-
New hope for hard-to-treat t-cell lymphoma: drug combo plus radiation before transplant
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating patients with T-cell non-Hodgkin lymphoma that has come back after a period of impro…
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New stem cell shot aims to ease knee arthritis pain
Disease control Recruiting nowStromaForte injection for knee OA
Phase: PHASE2, PHASE3 • Sponsor: Cellcolabs Clinical SPV Limited • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Could a constipation drug slow cancer growth? new trial tests axelopran
Disease control Recruiting nowThe primary objective of this single arm, open label, phase II trial is to determine if axelopran use impacts cancer control in patients with advanced cancers of the lung, breast, pancreas, and prostate. The primary study period for assessing the primary aim is through day 43 (6 …
Phase: PHASE2 • Sponsor: HealthPartners Institute • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug hunts and kills stubborn bone marrow cancer cells
Disease control TerminatedThis phase I trial tests the safety, side effects and best dose of lintuzumab-ac225 for the treatment of patients with high risk myelodysplastic syndrome that has not responded to previous treatment (refractory). Lintuzumab-ac225 is a monoclonal antibody, called lintuzumab, linke…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
New hope for liver cancer: drug combo targets patients who failed immunotherapy
Disease control Not yet recruitingThis is a Phase 2, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of fostrox in combination with lenvatinib compared with lenvatinib alone in patients with locally advanced or unresectable advanced hepatocellular carcinoma (HCC) who have ex…
Phase: PHASE2 • Sponsor: CHA University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Can an MS drug help preserve insulin production in type 1 diabetes?
Disease control Recruiting nowThis is a non-randomized, parallel-controlled, single-center, open-label clinical trial designed to evaluate the efficacy of dimethyl fumarate in preserving pancreatic beta-cell function in adults with type 1 diabetes, as well as its safety and tolerability in this population. E…
Phase: PHASE2, PHASE3 • Sponsor: Nanjing Medical University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New injection could help obese patients breathe better at night without CPAP
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive air…
Phase: PHASE3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC